High grade B-cell lymphoma Burkitt-like lymphoma – Diagnostics – Overview of Information and Clinical Research

High grade B-cell lymphoma Burkitt-like lymphoma is a rare and aggressive form of blood cancer that requires swift and accurate diagnosis to guide effective treatment decisions and improve patient outcomes.

Introduction: Who Should Undergo Diagnostics

People who experience certain warning signs should seek medical evaluation without delay. Because high grade B-cell lymphoma Burkitt-like lymphoma grows extremely fast, symptoms often appear suddenly and can worsen within just a few days. This rapid progression makes it essential to act quickly when concerning symptoms develop.^[1]

Anyone who notices rapidly growing lumps or masses, especially in the abdomen, neck, armpit, or groin area, should consult a doctor immediately. These swellings can grow at an alarming rate, sometimes becoming noticeably larger within days. The speed at which symptoms develop is one of the key features that distinguishes this condition from slower-growing lymphomas.^[2]

People experiencing unexplained abdominal pain, persistent nausea, vomiting, or changes in bowel habits should also seek prompt medical attention. Because this type of lymphoma commonly affects the abdomen and bowel, digestive symptoms can be early warning signs that shouldn’t be ignored. Additional concerning symptoms include unexplained weight loss, drenching night sweats that soak through clothing and bedsheets, persistent fever without an obvious cause, and extreme tiredness that doesn’t improve with rest.^[4]

Individuals with weakened immune systems face higher risk and should be particularly vigilant. This includes people living with HIV or AIDS, organ transplant recipients taking immunosuppressive medications, and those with inherited immune deficiencies. In these populations, the disease can develop more readily because the immune system cannot effectively control abnormal cell growth.^[2]

⚠️ Important

Because high grade B-cell lymphoma Burkitt-like lymphoma is one of the fastest growing cancers known to medicine, with a doubling time of around 25 hours, early detection and prompt medical evaluation are absolutely critical. Waiting even a few days to seek medical attention when symptoms appear can make a significant difference in treatment outcomes.

Classic Diagnostic Methods

Diagnosing high grade B-cell lymphoma Burkitt-like lymphoma requires multiple tests and procedures to confirm the disease and distinguish it from other similar conditions. The diagnostic process typically begins with a thorough physical examination where the doctor checks for swollen lymph nodes in the neck, armpits, groin, and other areas. A neurological exam, which tests how well the brain and nerves are working, may also be performed to check if the cancer has affected the central nervous system.^[12]

Blood tests play an important role in the initial evaluation. These tests can sometimes reveal the presence of lymphoma cells circulating in the bloodstream. Blood work also measures levels of lactate dehydrogenase (LDH), an enzyme that is often elevated in people with lymphoma. High LDH levels can indicate rapid cell turnover, which is characteristic of aggressive lymphomas. Additionally, blood tests check for infections that might increase the risk of developing this type of lymphoma, such as Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV).^[12]

Imaging tests create detailed pictures of the inside of the body and help doctors see where the lymphoma is located and how far it has spread. Computed tomography (CT) scans use X-rays taken from different angles and combine them with computer processing to create cross-sectional images of bones, blood vessels, and soft tissues. Positron emission tomography (PET) scans use a small amount of radioactive sugar to highlight areas of high metabolic activity, which cancer cells typically display. If doctors suspect the cancer may have reached the brain or spinal cord, they may order a magnetic resonance imaging (MRI) scan, which uses powerful magnets and radio waves to produce detailed images of soft tissues.^[12]

The definitive diagnosis requires obtaining tissue samples for laboratory examination. A lymph node biopsy involves removing all or part of an enlarged lymph node. This can be done through a surgical procedure or with a needle, depending on the location and size of the lymph node. In the laboratory, specialized doctors called pathologists examine the tissue under a microscope to look for characteristic features of high grade B-cell lymphoma Burkitt-like lymphoma.^[12]

Bone marrow aspiration and biopsy are procedures used to collect samples from the bone marrow, the soft, spongy tissue inside bones where blood cells are made. During bone marrow aspiration, a needle is used to draw out a sample of the liquid portion of the marrow. In a bone marrow biopsy, a slightly larger needle removes a small core of solid bone marrow tissue. These samples are typically taken from the hip bone. Laboratory analysis of bone marrow samples can reveal whether lymphoma cells have spread to the bone marrow, which happens in many cases of this aggressive disease.^[12]

What makes accurate diagnosis particularly challenging is that high grade B-cell lymphoma Burkitt-like lymphoma can look very similar to another aggressive B-cell lymphoma called diffuse large B-cell lymphoma (DLBCL) when examined under a microscope. Because these diseases require different treatment approaches, it is critically important to distinguish between them. This is why experts strongly recommend that patients seek evaluation by a lymphoma specialist who has extensive experience in diagnosing and treating these complex conditions.^[2]

Molecular and genetic testing provides crucial information for accurate diagnosis. One of the hallmark features of Burkitt lymphoma is a genetic change called MYC translocation. This occurs when a piece of chromosome containing the MYC gene breaks off and attaches to another chromosome, causing the MYC gene to become overactive and drive uncontrolled cell growth. High grade B-cell lymphoma with dual genetic abnormalities affecting MYC along with either BCL2 or BCL6 genes represents a specific category that shares features with both Burkitt lymphoma and DLBCL but requires distinct treatment considerations.^[2]^[8]

Testing may also include examination of cerebrospinal fluid, the clear liquid that surrounds the brain and spinal cord. This fluid can be obtained through a procedure called lumbar puncture or spinal tap. Because this type of lymphoma has a tendency to spread to the central nervous system, checking the cerebrospinal fluid for cancer cells is an important part of the diagnostic workup.^[15]

Diagnostics for Clinical Trial Qualification

Clinical trials testing new treatments for high grade B-cell lymphoma Burkitt-like lymphoma use specific diagnostic tests and criteria to determine which patients can participate. These studies require precise documentation of the disease to ensure that participants truly have the condition being studied and to measure how well experimental treatments work.^[10]

Enrollment in clinical trials typically requires confirmation of the diagnosis through tissue biopsy with detailed histologic examination. This microscopic analysis looks at the appearance, size, and arrangement of cancer cells. The pathologist examines cell features such as the shape of the nucleus, the presence of numerous cell divisions (mitotic figures), and the characteristic “starry sky” pattern created by scattered immune cells called macrophages consuming dead cancer cells.^[6]

Immunohistochemistry testing is essential for clinical trial qualification. This technique uses special antibodies to detect specific proteins on the surface of cancer cells. High grade B-cell lymphoma Burkitt-like lymphoma cells typically express certain markers including CD19, CD20, CD22, and CD79a, which identify them as B cells. They also show a very high proliferation index, often approaching 100%, measured by a marker called Ki-67. This indicates that nearly all the cancer cells are actively dividing, which explains the disease’s extraordinarily rapid growth rate.^[6]

Cytogenetic testing examines chromosomes under a microscope to identify structural changes. Molecular tests that look for specific gene rearrangements are mandatory for most clinical trials. These tests confirm the presence of MYC translocation and check for additional genetic abnormalities involving BCL2 or BCL6 genes. The specific combination of genetic changes helps classify the lymphoma into precise categories, which determines eligibility for particular clinical trials.^[8]

Staging procedures are required to determine the extent of disease spread throughout the body. Clinical trials use standardized staging systems that categorize patients based on which parts of the body are affected by lymphoma. Complete staging typically includes CT scans of the chest, abdomen, and pelvis, PET scans to identify all areas of active disease, bone marrow biopsy, and examination of cerebrospinal fluid. This comprehensive evaluation helps researchers stratify patients into risk groups and assess whether experimental treatments are working.^[12]

Blood tests measuring organ function are standard requirements for clinical trial participation. These include tests of kidney function (creatinine and blood urea nitrogen), liver function (bilirubin, alanine aminotransferase, and aspartate aminotransferase), and blood cell counts (complete blood count). Normal or near-normal organ function is often required because many experimental treatments can stress the kidneys, liver, or bone marrow. Researchers need to ensure that participants can safely tolerate the treatments being studied.^[10]

Testing for infectious diseases is another standard component of clinical trial screening. Blood tests for HIV, hepatitis B, and hepatitis C are commonly required because these infections can affect treatment safety and effectiveness. Patients with these infections may be excluded from some trials or may be eligible for specialized studies designed specifically for people with weakened immune systems.^[12]

⚠️ Important

Clinical trials often have strict eligibility criteria based on diagnostic test results. While this might seem exclusionary, these requirements protect participants and ensure that research findings are scientifically valid. If you don’t qualify for one clinical trial, you might be eligible for another. Your healthcare team can help identify trials that match your specific situation.

Performance status assessment is a required component of clinical trial evaluation. Doctors use standardized scales to measure a patient’s ability to perform daily activities and self-care. This assessment helps determine whether a person is well enough to participate in a study and tolerate intensive treatments. Most trials require participants to have sufficient physical function to care for themselves and spend most of their waking hours out of bed.^[10]

Baseline quality of life questionnaires are increasingly used in clinical trials. These ask patients to rate their symptoms, physical functioning, emotional well-being, and overall quality of life before treatment begins. Researchers use these assessments to measure not just whether a treatment extends survival, but whether it improves or maintains quality of life during and after treatment.^[10]

Response evaluation during and after treatment follows standardized criteria in clinical trials. PET scans performed at specific timepoints help researchers determine whether the experimental treatment is working. The intensity of radioactive tracer uptake in lymphoma sites is measured and compared to uptake in the liver and blood vessels. Complete disappearance of abnormal uptake indicates complete response, while persistent or increased uptake suggests the treatment isn’t working effectively.^[12]

Prognosis and Survival Rate

Prognosis

The prognosis for patients with high grade B-cell lymphoma Burkitt-like lymphoma varies significantly depending on several factors. In children treated with intensive chemotherapy regimens, the disease prognosis is generally excellent, with many achieving long-term cure. However, the prognosis tends to be poorer in adults, particularly older adults, even with aggressive treatment approaches.^[3]

Several factors influence disease outcomes. The extent of disease spread at diagnosis plays a critical role, with limited-stage disease generally having better outcomes than advanced-stage disease. The level of LDH in the blood reflects the total amount of rapidly dividing cancer cells in the body, and higher levels typically indicate a worse prognosis. Whether the lymphoma has spread to the bone marrow or central nervous system also significantly impacts treatment success.^[6]

The patient’s overall health status and ability to tolerate intensive chemotherapy affects prognosis. Younger patients with good organ function and no other serious medical conditions generally have better outcomes than older or frail patients. The specific genetic characteristics of the lymphoma cells also influence prognosis, with certain genetic patterns associated with more aggressive behavior or resistance to standard treatments.^[3]

High grade B-cell lymphoma Burkitt-like lymphoma is considered one of the most aggressive cancers, but it is also potentially curable when diagnosed and treated promptly. Unlike some slower-growing lymphomas that cannot be cured but can be controlled for years, this aggressive disease must be treated immediately with intensive therapy. The rapid growth rate that makes it dangerous also makes it highly sensitive to chemotherapy, because cancer-killing drugs work best against rapidly dividing cells.^[1]

Survival Rate

More than 70% of patients with aggressive non-Hodgkin lymphomas, including high grade B-cell lymphoma Burkitt-like lymphoma, can be cured with modern intensive treatment approaches. This represents a remarkable achievement in cancer medicine. However, it’s important to understand that survival rates vary significantly based on individual patient and disease characteristics.^[14]

Most relapses, if they occur, happen within the first two years after completing treatment. Patients who remain in remission for two years have a good chance of being cured. The risk of the disease returning after this point is relatively low, though late relapses can occasionally occur. Long-term survival is possible for many patients who achieve complete remission with initial treatment.^[14]

For patients whose disease doesn’t respond to initial treatment or comes back after remission, the prognosis is more challenging. Relapsed or refractory disease is more difficult to treat and has lower cure rates. However, some patients can still achieve long-term remission with salvage therapies, including different chemotherapy combinations or stem cell transplantation.^[6]

#1 Clinical Trials Search in Europe